Sugammadex

Generic name
Sugammadex
Brand name
ATC Code
V03AB35
Compare …

Sugammadex

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

It does not bind to plasma proteins or erythrocytes. It is not metabolized. It is excreted almost entirely in unchanged form in the urine.

  Clearance (mL/min)
  Vd (L)
 T1/2 (h)
Neonate (15 days; 3,8 kg) 13 1,1 1,3
Infant (6 months; 7,9 kg) 12 1,8 2,2
Toddler (1,5 yr; 11 kg) 16 2,5 2,1
Young child (3,5 yr; 15 kg) 22 3,4 2,1
Older child (9 yr; 29 kg)
 39 5,8 2,1
Adolescent (15 yr; 56 kg)
 71 10 2,0
Adult (40 yr; 75 kg) 84 13 2,2

[SmPC Bridion]

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Standard relief of neuromuscular blockade induced by rocuronium
  • Intravenous
    • 1 month up to 18 years

      • On return of T2: 2 mg/kg/dose
        For recovery of at least 1-2 PTC: 4 mg/kg/dose

      • In emergency situations (without presentation of T2) higher doses – of up to 16 mg/kg – may be needed to lift the block urgently.

         

    • Term neonate

      • On return of T2: 2 mg/kg/dose
        For recovery of at least 1-2 PTC: 4 mg/kg/dose

      • In emergency situations (without presentation of T2) higher doses – of up to 16 mg/kg – may be needed to lift the block urgently.

         

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ALL OTHER THERAPEUTIC PRODUCTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Antidotes
V03AB27
V03AB16
V03AB24
V03AB25
V03AB33
V03AB17
V03AB15
V03AB13
V03AB19
V03AB14
V03AB06
Iron chelating agents
V03AC03
V03AC02
V03AC01
Drugs for treatment of hyperkalemia and hyperphosphatemia
V03AE07
V03AE01
V03AE02
V03AE01
Detoxifying agents for antineoplastic treatment
V03AF03
V03AF01
V03AF07
Drugs for treatment of hypoglycemia
V03AH01
Other therapeutic products
V03AX03
DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT
V03AF03
V03AF01
V03AF07
OTHER THERAPEUTIC PRODUCTS
V03AX03

References

  1. Merck Sharp & Dohme B.V. , SmPC Bridion (EU/1/08/466/001) Rev 20, 14-02-2022, www.emea.europa.eu
  2. Mirakhur RK, Sugammadex in clinical practice, Anaesthesia, 2009, 64 (0), 45-54
  3. Sparr HJ et al, Sugammadex Neues pharmakologisches Konzept zur Antagonisierung von Rocuronium und Vecuronium, Anaesthesist, 2009, 58, 66–80
  4. Buchanan CCR et al, The transversus abdominis plane (TAP) block in neonates and infants – results of an audit, Pediatric Anesthesia 21, 2011, 21, 1073–1088
  5. Plaud B, et al, Reversal of Rocuronium-induced Neuromuscular Blockade with Sugammadex in Pediatric and Adult Surgical Patients, Anesthesiology, 2009, 110, 284–94
  6. Werkgroep Neonatale Farmacologie NVK sectie Neonatologie., Expert opinion, 8 May 2024
  7. Franz AM, et al., Case series of 331 cases of sugammadex compared to neostigmine in patients under 2 years of age., Paediatr Anaesth., 2019, 29(6), 591-6
  8. Alonso A, et al, Reversal of rocuronium-induced neuromuscular block by sugammadex in neonates: 10AP1-3, European Journal of Anaesthesiology, 2014, 31, 163
  9. Langley RJ, et al, The presumed central nervous system effects of rocuronium in a neonate and its reversal with sugammadex. , Paediatr Anaesth., 2016, 26(1), 109-11
  10. Langley RJ, et al, The presumed central nervous system effects of rocuronium in a neonate and its reversal with sugammadex., Paediatr Anaesth., 2016, 26(1), 109-11
  11. Merck Sharp & Dohme B.V., SmPC Bridion (EU/1/08/466/001) Rev 24, 10-02-2025, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose